“Breaking news: Controlled substance compliance failures rock major corporation.”

This is the kind of headline that doesn’t just attract attention. It plants doubt in your whole organization.

Imagine this:

A distributor notices unusual order growth for a controlled substance. It’s flagged, but no one follows up. Six months later, regulators investigate. The distributor is

As required by the “SUPPORT for Patients and Communities Act” (Public Law 115-217), DEA just announced that it has implemented a new tool to provide drug manufacturers and distributors with access to anonymized ARCOS information.

This an enhancement to DEA’s existing tool that previously provided very limited ARCOS information.  The new functionality in the tool